Plasma-first: accelerating lung cancer diagnosis and molecular profiling through liquid biopsy.

ABSTRACT:

Introduction

Molecular profiling of tumor tissue is the gold standard for treatment decision-making in advanced non-small cell lung cancer (NSCLC). Results may be delayed or unavailable due to insufficient tissue, prolonged wait times for biopsy, pathology assessment and testing. We piloted the use of plasma testing in the initial diagnostic workup for patients with suspected advanced lung cancer.

Methods

Patients with ⩽15 pack-year smoking history and suspected advanced lung cancer referred to the lung cancer rapid diagnostic program underwent plasma circulating-tumor DNA testing using a DNA-based mutation panel. Tissue testing was performed per standard of care, including comprehensive next-generation sequencing (NGS). The primary endpoint was time from diagnostic program

SUBMITTER: Garcia-Pardo M 

PROVIDER: S-EPMC9500258 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature